Urgent Recall Issued for Ramipril 2.5mg Capsules Due to Packaging Error
On May 28, 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an urgent recall for one batch of Crescent Pharma Limited ramipril 2.5mg capsules, a widely prescribed blood pressure medication. The recall follows a complaint from a healthcare professional who discovered two blister strips of 10mg capsules inside a sealed box that had been labelled as 2.5mg. The error appears to have occurred during the packaging process, with both dosages manufactured at the same facility.
Patients are being urged to check their medication packaging for batch number GR155023. If the outer carton matches this batch, they must verify that the strength on the carton matches the blister strips inside. Anyone who finds 10mg capsules in a 2.5mg box should not take the medicine and should return it to their dispensing pharmacy immediately. The MHRA warns that taking a higher dose than intended can lead to side effects such as light-headedness, fainting, fatigue, or altered kidney function, which may be more serious for vulnerable patients.
What Patients Need to Do
Dr Alison Cave, MHRA Chief Safety Officer, advised: "If you take Crescent Pharma Limited ramipril 2.5mg capsules, check the packaging for batch number GR155023. The batch number and expiry date information can be found on the outer carton. If you have received this batch, check that the medication strength on the carton matches the blister strips inside."
She added: "If the 2.5mg carton of Crescent Pharma Limited ramipril contains blister strips that are labelled as ramipril 10mg capsules, do not to take the medicine and contact your dispensing pharmacy. If the carton contains blister strips that are correctly labelled as Crescent Pharma Limited ramipril 2.5mg capsules, you do not need to take further action and should continue to take your medicine as usual."
Patients who believe they may have taken a 10mg capsule in error and are experiencing symptoms such as dizziness, fainting, tiredness, or changes in kidney function are urged to seek medical advice. Dr Cave emphasized that "any possible impact of taking a higher dose of ramipril should be assessed by a healthcare professional to determine whether any examination or tests are needed."
Why Ramipril Matters: A Lifesaving Drug for Millions
Ramipril is an ACE inhibitor that works by widening blood vessels, making it easier for the heart to pump blood around the body. It is commonly prescribed for high blood pressure (hypertension), heart failure, kidney disease, and to prevent heart attacks. According to the NHS, high blood pressure affects more than one in four adults in the UK, and ramipril is one of the most frequently prescribed treatments.
The drug is particularly important for older adults, who are at higher risk of cardiovascular events. A dosing error could have serious consequences for these patients, especially those with pre-existing kidney problems or those taking other medications that affect blood pressure. The recall highlights the critical importance of pharmaceutical quality control, as even a single packaging mistake can put patients at risk.
This incident also comes at a time when the NHS is under significant strain, as reported in recent coverage of NHS Under Pressure: UK Doctors Strike as Global Healthcare Strains Intensify. With healthcare resources already stretched, any additional patient harm from medication errors could further burden the system.
The Scope of the Recall: Batch GR155023
The recall applies specifically to Crescent Pharma Limited ramipril 2.5mg capsules with batch number GR155023. The MHRA has confirmed that the affected product was distributed across the UK. Patients are advised to check the outer carton, which displays both the batch number and expiry date. If the carton contains blister strips labelled as 10mg, they should not be taken.
Crescent Pharma Limited initiated the recall as a precautionary measure after the packaging error was identified. The company is cooperating with the MHRA to investigate the root cause and prevent future occurrences. Pharmacies and GP practices have been notified and are ready to assist patients with affected packs.
It is important to note that this recall does not affect all ramipril products. Patients taking ramipril from other manufacturers or different batches are not affected and should continue their medication as normal. The MHRA stressed that only Crescent Pharma ramipril 2.5mg capsules from batch GR155023 are subject to the recall.
Broader Implications: Patient Safety and Pharmaceutical Oversight
This recall underscores the ongoing challenges in pharmaceutical manufacturing and the importance of robust regulatory oversight. While packaging errors are rare, they can have serious health consequences when they involve drugs with narrow therapeutic windows. Ramipril is a potent medication, and a fourfold increase in dose — from 2.5mg to 10mg — could cause hypotension, kidney impairment, or other adverse effects, particularly in elderly or debilitated patients.
The MHRA's swift action in issuing the recall reflects the UK's commitment to patient safety. However, the incident also raises questions about how such errors occur and whether more stringent checks are needed in the packaging process. Pharmaceutical companies are expected to have multiple layers of quality control, and a failure in this system could prompt regulatory scrutiny.
For patients, the recall is a reminder to always check medication packaging, especially when starting a new prescription or refilling. The NHS advises patients to verify the name, strength, and batch number of their medicines, and to report any discrepancies to their pharmacist. In an era of complex supply chains and multiple manufacturers, vigilance at the patient level can be a critical safety net.
What This Changes: A Call for Heightened Awareness
While this recall is limited to a single batch, it has broader implications for how patients and healthcare providers approach medication safety. The incident highlights the need for clear communication between pharmacists, prescribers, and patients. It also reinforces the importance of reporting adverse events to the MHRA's Yellow Card scheme, which helps regulators track and respond to safety issues.
In the wake of this recall, patients who rely on ramipril should not stop taking their medication without consulting a healthcare professional. Suddenly discontinuing blood pressure treatment can lead to dangerous spikes in blood pressure, increasing the risk of stroke or heart attack. Instead, patients should check their packaging, and if affected, contact their pharmacy for a replacement.
The recall also serves as a cautionary tale for the pharmaceutical industry. With millions of prescriptions dispensed annually, even a small error rate can affect a significant number of patients. Investing in advanced packaging technologies, such as barcode verification and automated inspection systems, could help prevent similar mistakes in the future.
Looking Ahead: Ensuring Trust in Medications
As the NHS continues to face challenges from doctor strikes and rising demand, as highlighted in NHS Under Pressure: UK Doctors Strike as Global Healthcare Strains Intensify, maintaining public trust in the safety of prescribed medications is paramount. The MHRA's transparent handling of this recall, including the release of images showing the correct and incorrect packaging, is a positive step. Patients are encouraged to visit the MHRA website for official updates and to stay informed.
In summary, anyone taking Crescent Pharma ramipril 2.5mg capsules should check their box for batch number GR155023. If the blister strips inside are labelled 10mg, do not take them and return the pack to your pharmacy. If the strips match the carton, continue as normal. For those experiencing symptoms after taking a higher dose, seek medical advice without delay.
This recall is a reminder that even trusted medications can sometimes be subject to human error, but with prompt action and clear guidance, patient safety can be protected.
Comments